1. 人工晶体业务整体稳健，隐形眼镜加速爬坡，集采及产品结构改变致使盈利水平暂时承压。分业务板 块看，2024 年公司"普诺明""全视"等人工晶状体销量同比增长44.93%，贡献营收5.88 亿元 （+17.66%）；"普诺瞳"角膜塑形镜销量同比增长2.4%，贡献营收2.36 亿元（+8.03%），离焦镜等加速 放量，带动近视防控板块营收实现20.8%的增长；隐形眼镜随着产能持续爬坡，实现销量同比增长 241.11%，贡献营收4.26 亿元（+211.84%）。随着人工晶体集采全面落地执行、价格水平下调，而高端 晶体占比仍较低，以及低毛利隐形眼镜业务占比进一步提升至30.21%（+15.85pct），公司整体毛利率 下滑至66.23%（-9.78pct）；25Q1，人工晶体业务持续受集采影响，价格下调，终端手术量减少，同时 角膜塑形镜市场竞争加剧、出厂价格略有下调，加之隐形眼镜业务利润贡献有限，公司整体毛利率进一 步下滑至64.6%。公司在产品端持续推进晶体、近视防控的高端产品上市，加速隐形眼镜业务的生产规 模扩大和生产端优化，同时在渠道端推进全球网络建设，国内协同院内院外、零售等多渠道销售，海外 覆盖德国、 ...

Core Viewpoint - Aibo Medical continues to drive high-quality development through ESG principles, showcasing a balance between technological leadership and social responsibility, with a focus on core products and a dual strategy of "medical + consumer" [2] Environmental Dimension - Aibo Medical has been recognized as a water-saving enterprise in Beijing and has implemented water-saving technologies such as membrane separation and rainwater harvesting for irrigation [3] - The company has achieved ISO 50001 energy management certification and improved energy efficiency through various initiatives, including variable frequency technology and energy-saving lighting, expected to save nearly 10,000 kWh annually [3] Social Dimension - Aibo Medical has established the "Puno Tong Starfire Program" in collaboration with five universities to cultivate talent and has organized 61 academic conferences, enhancing industry standards and academic influence [3] - The company has partnered with Meituan to launch the first 24-hour smart store for contact lenses, improving consumer convenience through automation [3] Governance Dimension - Aibo Medical's R&D investment reached 160 million yuan in 2024, a year-on-year increase of 20.8%, with a total of 417 patent applications and 256 granted patents [5] - The company has been recognized for its governance transparency, receiving an A-level rating for information disclosure from the Shanghai Stock Exchange for two consecutive years [2] ESG Challenges - Aibo Medical was removed from the "Huaxia-Wind ESG Dandelion 50 Index" due to a decline in ESG scores, indicating areas for improvement in climate action and resource recycling disclosures [6] - The company lacks quantifiable targets for carbon emissions reduction and renewable energy usage, which are critical for assessing its climate action effectiveness [7] - There is insufficient disclosure regarding waste management and resource recycling, making it difficult to evaluate the company's environmental performance [7][8] Employee Welfare - While Aibo Medical has implemented measures for employee rights and training, there is a need for improvement in the depth and breadth of employee care compared to industry leaders [8] - The company has not disclosed detailed employee demographics or turnover rates, limiting external understanding of its human resource management practices [8] Quality Control - Aibo Medical faced a product recall due to a quality issue with a specific batch of soft hydrophilic contact lenses, highlighting the importance of quality management alongside capacity expansion [9]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown strong revenue growth in 2024, achieving 1.41 billion yuan, a year-on-year increase of 48.24%, while net profit attributable to the parent company reached 388 million yuan, up 27.77% [1][2] - The growth in the contact lens segment is robust, with a significant increase in revenue, and the company is optimistic about the launch of high-end new products in 2025 [2][3] - The profit growth rate is lagging behind revenue growth due to fluctuations in gross margins, influenced by intensified competition in the artificial lens and orthokeratology markets [2][3] Revenue and Profit Analysis - In 2024, the company reported revenue of 1.41 billion yuan, with a gross margin of 66.23%, down 9.78 percentage points year-on-year [2] - For Q1 2025, revenue was 357 million yuan, a 15.07% increase year-on-year, but net profit decreased by 10.05% [1][2] - The company’s gross margins for 2024 and Q1 2025 were 66.23% and 64.60%, respectively, reflecting the impact of competitive pricing and a higher proportion of lower-margin products [2] Segment Performance - Contact lenses generated revenue of 426 million yuan in 2024, a remarkable increase of 211.84%, with a gross margin of 26.18% [3] - Revenue from artificial lenses was 588 million yuan, up 17.66%, with a gross margin of 89.16% [3] - The orthokeratology lens segment saw revenue of 236 million yuan, an 8.03% increase, with a gross margin of 85.68% [3] Market Expansion - Domestic revenue reached 1.36 billion yuan in 2024, a 49.52% increase, while overseas revenue was 46 million yuan, up 16.73% [4] - The company has established a comprehensive domestic sales network covering over 6000 hospitals and optical centers across 31 provinces and municipalities [4] - Internationally, the company has expanded its sales network to Europe, Asia, and Oceania, with products recognized in over 30 countries [4] Financial Forecast - Revenue projections for 2025-2027 are 1.82 billion yuan, 2.38 billion yuan, and 3.07 billion yuan, with year-on-year growth rates of 29.2%, 30.5%, and 29.1% respectively [4] - Net profit forecasts for the same period are 469 million yuan, 585 million yuan, and 725 million yuan, with growth rates of 20.8%, 24.8%, and 23.9% respectively [4]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown strong revenue growth in 2024, achieving 1.41 billion yuan, a year-on-year increase of 48.24%, while net profit attributable to shareholders reached 388 million yuan, up 27.77% [1] - The growth in the contact lens segment is robust, with a significant increase in revenue, and the company is optimistic about the launch of high-end new products in 2025 [2][3] - The profit growth rate is lagging behind revenue growth due to fluctuations in gross margins, influenced by increased competition and pricing pressures in the artificial lens and orthokeratology markets [2] Revenue and Profit Analysis - In 2024, the company reported revenue of 1.41 billion yuan, with a gross margin of 66.23%, down 9.78 percentage points year-on-year [2] - For Q1 2025, revenue was 357 million yuan, reflecting a 15.07% year-on-year growth, but net profit decreased by 10.05% [1] - The contact lens segment generated 426 million yuan in revenue, a remarkable increase of 211.84%, while the artificial lens segment saw revenue of 588 million yuan, up 17.66% [3] Market Expansion - Domestic sales reached 1.36 billion yuan, a 49.52% increase, while overseas sales were 46 million yuan, up 16.73% [4] - The company has established a comprehensive domestic sales network covering over 6000 hospitals and optical centers across 31 provinces and regions [4] - Internationally, the company has expanded its sales network to Europe, Asia, and Oceania, with products exported to over 30 countries [4] Financial Forecast - Revenue projections for 2025-2027 are 1.82 billion yuan, 2.38 billion yuan, and 3.07 billion yuan, respectively, with year-on-year growth rates of 29.2%, 30.5%, and 29.1% [4] - Net profit forecasts for the same period are 469 million yuan, 585 million yuan, and 725 million yuan, with growth rates of 20.8%, 24.8%, and 23.9% [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a robust revenue growth of 48.24% year-on-year for 2024, achieving total revenue of 1.41 billion yuan and a net profit of 388 million yuan, which is a 27.77% increase year-on-year [3] - The first quarter of 2025 showed a revenue of 357 million yuan, reflecting a year-on-year growth of 15.07%, although net profit decreased by 10.05% to 93 million yuan [3] - The company is positioned as a platform-type enterprise with strong R&D capabilities and commercial potential, with a focus on artificial crystalline lenses and myopia control products [8] Summary by Sections Business Performance - The artificial crystalline lens segment saw sales volume of approximately 1.7385 million pieces in 2024, a year-on-year increase of 44.93%, generating sales revenue of about 588 million yuan, up 17.66% year-on-year [4] - The myopia control business generated approximately 336 million yuan in revenue, a growth of 20.79% year-on-year, with OK lens sales contributing 236 million yuan, an 8.03% increase [5] - The vision care segment reported revenue of approximately 426 million yuan, a significant increase of 211.84% year-on-year, with sales volume reaching 214 million pieces [6] Financial Projections - Revenue projections for 2025, 2026, and 2027 are estimated at 1.763 billion yuan, 2.247 billion yuan, and 2.810 billion yuan respectively, with growth rates of 25.1%, 27.4%, and 25.1% [9] - Net profit forecasts for the same years are 468 million yuan, 610 million yuan, and 776 million yuan, with growth rates of 20.5%, 30.3%, and 27.3% [9] - The expected EPS for 2025, 2026, and 2027 are 2.47 yuan, 3.22 yuan, and 4.10 yuan, with corresponding P/E ratios of 35x, 27x, and 21x [9] R&D and Market Position - The company invested approximately 159.82 million yuan in R&D in 2024, representing 11.33% of its revenue, indicating a strong commitment to innovation [8] - The company has established a sales network covering over 6,000 hospitals and vision centers across 31 provinces, enhancing its market reach [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a robust revenue growth of 48.24% year-on-year for 2024, achieving total revenue of 1.41 billion yuan and a net profit of 388 million yuan, which is a 27.77% increase year-on-year [3] - The first quarter of 2025 showed a revenue of 357 million yuan, reflecting a year-on-year growth of 15.07%, although net profit decreased by 10.05% [3] - The company is positioned as a platform-type enterprise with strong R&D capabilities and commercial potential, with a focus on expanding its product offerings in the ophthalmic sector [8] Summary by Sections Business Performance - The artificial lens business saw sales volume reach approximately 1.7385 million pieces in 2024, a year-on-year increase of 44.93%, generating sales revenue of about 588 million yuan, up 17.66% year-on-year [4] - The myopia prevention business generated approximately 336 million yuan in revenue, a growth of 20.79% year-on-year, with OK lens sales contributing 236 million yuan [5] - The vision care business reported revenue of approximately 426 million yuan, a significant increase of 211.84% year-on-year, with sales volume reaching 214 million pieces [6] Financial Projections - Revenue projections for 2025, 2026, and 2027 are estimated at 1.763 billion yuan, 2.247 billion yuan, and 2.810 billion yuan, respectively, with growth rates of 25.1%, 27.4%, and 25.1% [9] - The net profit for the same years is projected to be 468 million yuan, 610 million yuan, and 776 million yuan, with growth rates of 20.5%, 30.3%, and 27.3% [9] - The expected EPS for 2025, 2026, and 2027 are 2.47 yuan, 3.22 yuan, and 4.10 yuan, with corresponding P/E ratios of 35x, 27x, and 21x [9] R&D and Market Position - The company invested approximately 159.82 million yuan in R&D in 2024, representing 11.33% of its revenue, indicating a strong commitment to innovation [8] - The company has established a sales network covering over 6,000 hospitals and vision centers across China, enhancing its ability to commercialize new products [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.41 billion yuan in 2024, representing a year-on-year growth of 48.24%, and a net profit attributable to shareholders of 388 million yuan, up 27.77% year-on-year [8] - The first quarter of 2025 is expected to face short-term pressure due to the impact of national centralized procurement policies on artificial crystalline lenses, leading to a decrease in surgical volumes and prices [8] - The company anticipates a recovery in its artificial lens business as new products, such as bifocal lenses and PR crystals, gradually gain market traction [8] Financial Summary - Total revenue forecast for 2024 is 1.41 billion yuan, with a projected growth rate of 48.24% [9] - Net profit attributable to shareholders is expected to be 388 million yuan in 2024, with a growth rate of 27.77% [9] - Earnings per share (EPS) is projected to be 2.05 yuan in 2024, with a price-to-earnings (P/E) ratio of 41.96 [9] - The company’s total assets are estimated to reach 4.08 billion yuan by 2025, with a debt-to-asset ratio of 24.01% [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.41 billion yuan in 2024, representing a year-on-year growth of 48.24%, and a net profit attributable to shareholders of 388.4 million yuan, up 27.77% year-on-year [8] - The first quarter of 2025 is expected to face short-term pressure due to the impact of national centralized procurement policies on artificial crystalline lenses, leading to a decrease in surgical volumes and prices [8] - The company anticipates a recovery in its artificial lens business as new products, such as bifocal lenses and PR crystals, gradually gain market traction [8] Financial Forecasts - Total revenue projections for the company are as follows: - 2023: 951.18 million yuan - 2024: 1,410.02 million yuan - 2025: 1,832.77 million yuan - 2026: 2,316.38 million yuan - 2027: 2,988.12 million yuan - Net profit attributable to shareholders is forecasted as: - 2023: 303.98 million yuan - 2024: 388.40 million yuan - 2025: 465.50 million yuan - 2026: 584.36 million yuan - 2027: 717.18 million yuan [1][9] - The earnings per share (EPS) estimates are: - 2023: 1.60 yuan - 2024: 2.05 yuan - 2025: 2.46 yuan - 2026: 3.08 yuan - 2027: 3.78 yuan [1][9] Market Data - The closing price of the company's stock is 85.98 yuan, with a market capitalization of 16,297.04 million yuan [5] - The price-to-earnings (P/E) ratio based on the latest diluted EPS is projected to be: - 2024: 41.96 - 2025: 35.01 - 2026: 27.89 - 2027: 22.72 [1][9]

科创板融资余额较前一交易日增加4.09亿元，融券余额减少1200.35万元。302股融资余额环比增加，123 股融券余额环比增加。 证券时报·数据宝统计显示，截至4月23日，科创板两融余额合计1501.25亿元，较上一交易日增加3.97亿 元。连续3个交易日增加。其中，融资余额合计1495.88亿元，较上一交易日增加4.09亿元；融券余额合 计5.37亿元，较上一交易日减少1200.35万元。 | 代码 | 简称 | 最新融资余额 | 融资余额环比增 | 最新融券余额 | 融券余额环比增 | 当日涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | | | (万元） | 减（%） | (万元） | 减（%） | （%） | | 688050 | 爱博 | 35225.09 | 60.16 | 234.76 | -20.87 | -20.00 | | | 医疗 | | | | | | | 688313 | 仕佳 | 51142.99 | 40.97 | 0.00 | | 4.30 | | | 光子 | | | | | | | 688757 | 胜科 | 4133 ...

每经记者 林姿辰 每经编辑 文多 国内人工晶体龙头在今年一季度似乎遇到了困难。 4月22日晚，爱博医疗发布2024年年报和2025年一季报。去年，公司营业收入和归母净利润的增速分别超过48%和27%，与此前发布的业绩快报基本一 致，出乎市场预料的是，今年一季度，公司实现归母净利润9255.81万元，同比减少10.05%。 近年罕见的单季度业绩下滑背后，是公司明星产品增长放缓。公司一季报显示，人工晶状体国家集采政策落地后，手术价格、人工晶状体出厂价格下滑。 在近视防控领域，市场竞争日益激烈，公司因此下调角膜塑形镜的出厂价格。 据公司2024年年报，公司新布局的隐形眼镜业务的毛利率不足明星产品（人工晶状体、角膜塑形镜）的1/3。虽然收入同比增长211.84%，但这似乎抚平不 了投资者的焦虑。公司一季报披露后次日（4月23日），爱博医疗股价跌停。 4月23日，《每日经济新闻》记者致电公司公开电话希望采访了解更多信息，并按要求发送了采访邮件，但截至发稿未获回复。 图片来源：由每经财报智能体一键生成 去年 OK镜收入首次超过隐形眼镜 在去年10月召开的电话会议中，公司方面曾表示："公司旗下普诺瞳OK镜三季度仍实现个位数 ...